Cargando…

Post-COVID-19 cholangiopathy: does SARS-CoV-2 play a relevant role in histopathological findings?

Detalles Bibliográficos
Autores principales:	de Almeida e Borges, Valéria Ferreira, Cotrim, Helma Pinchemel, Silva, Marcelo Costa, Costa Mendes, Liliana Sampaio, Cancela Penna, Francisco Guilherme, de Andrade, Antônio Ricardo Cardia Ferraz, Salomão, Frederico Chaves, Daud, Juliana, de Freitas, Luiz Antônio Rodrigues
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Thursday 23 June: Immune-mediated and cholestatic disease: Clinical aspects
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252388/ http://dx.doi.org/10.1016/S0168-8278(22)01035-2

Ejemplares similares

Cholangiopathy after severe COVID-19: what do we know so far?
por: de Almeida e Borges, Valéria Ferreira, et al.
Publicado: (2022)

Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis
por: Barreira, Ana, et al.
Publicado: (2022)

COVID-19 vaccine induced autoimmune hepatitis-a first case series from India
por: Iyengar, Sowmya, et al.
Publicado: (2022)

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
por: Jorgensen, Kristin, et al.
Publicado: (2022)

Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the european reference network on hepatological diseases (ERN RARE-LIVER)
por: Codoni, Greta, et al.
Publicado: (2022)

Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study
por: Hunyady, Peter, et al.
Publicado: (2022)

COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses
por: Canha, Maria Ines, et al.
Publicado: (2022)

Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine
por: Kulkarni, Anand, et al.
Publicado: (2022)

Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease
por: Samer, Al-Dury, et al.
Publicado: (2022)

Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines-a multicenter european study
por: Simão, André L., et al.
Publicado: (2022)

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
por: Kaewdech, Apichat, et al.
Publicado: (2022)

Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study
por: Iavarone, Massimo, et al.
Publicado: (2022)

Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program
por: Sypsa, Vana, et al.
Publicado: (2022)

Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia
por: Gulbiani, Lasha, et al.
Publicado: (2022)

mRNA COVID-19 vaccine effectiveness in liver transplant patients
por: Khan, Muhammad, et al.
Publicado: (2022)

Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan
por: Ashraf Hussain, Md Razeen, et al.
Publicado: (2022)

A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19
por: Lee, David Uihwan, et al.
Publicado: (2022)

Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant
por: John, Binu, et al.
Publicado: (2022)

Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease
por: Mateu, Carlos Alventosa, et al.
Publicado: (2022)

Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis
por: John, Binu, et al.
Publicado: (2022)

Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy
por: D’Ambrosio, Roberta, et al.
Publicado: (2022)

No effect of HBsAg positivity on antibody response after COVID-19 vaccine
por: Jargalsaikhan, Ganbolor, et al.
Publicado: (2022)

The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19
por: Cohen, Jason, et al.
Publicado: (2022)

Evaluation of immune response and disease flares in metobolic-associated fatty liver disease patients following SARS-CoV-2 vaccination: a prospective cohort study
por: Shi, Junping, et al.
Publicado: (2022)

Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain
por: Valencia, Jorge, et al.
Publicado: (2022)

The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada
por: Janjua, Naveed, et al.
Publicado: (2022)

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease
por: Younossi, Zobair, et al.
Publicado: (2022)

Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases
por: Li, Hu, et al.
Publicado: (2022)

High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells
por: Kenny, Susan, et al.
Publicado: (2008)

EP(2) and EP(4) receptors on muscularis resident macrophages mediate LPS-induced intestinal dysmotility via iNOS upregulation through cAMP/ERK signals
por: Tajima, Tsuyoshi, et al.
Publicado: (2012)

Intestinal epithelial suppressor of cytokine signaling 3 enhances microbial-induced inflammatory tumor necrosis factor-α, contributing to epithelial barrier dysfunction
por: Thagia, Imtiyaz, et al.
Publicado: (2014)

Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
por: De Vincentis, Antonio, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database
por: Tacke, Frank, et al.
Publicado: (2022)

The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients
por: Freitas, Marta, et al.
Publicado: (2022)

Effects of SARS-CoV2 pandemic in a cohort of italian NAFLD patients
por: Stefanini, Bernardo, et al.
Publicado: (2022)

From Nonalcoholic Steatohepatits to Steatotic Liver Disease: A Long Way
por: Cotrim, Helma Pinchemel
Publicado: (2023)

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
por: An, Ping, et al.
Publicado: (2020)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation
por: Pape, Simon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8mn95v93aef3sd9n92tdvseb0s